Patents by Inventor Varpu Marjomaki

Varpu Marjomaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUNGI-DERIVED COMPOSITION, ITS PRODUCTION PROCESS AND USES
    Publication number: 20240156104
    Abstract: A virucidal composition, a method of its manufacturing, related uses and end-user products are hereby provided. The composition includes a mixture of biologically active substances obtainable from selected fungal strains of Ganoderma lucidum (MUS12, MUS15, MUS18 and MUS23) by culturing the fungi in essentially liquid culture medium in a culture tank or a bioreactor in conditions essentially excluding agitation. The biologically active substances are obtained as a product excreted by mycelium of the above indicated G. lucidum strains and contain secondary metabolites, such as ganoderic acids and their derivatives. The composition has proved efficient in preventing the spread of viral infections. The composition can be used as a disinfecting agent for skin and nonliving surfaces and/or as an ingredient in preparation of personal care products.
    Type: Application
    Filed: February 18, 2022
    Publication date: May 16, 2024
    Inventors: Riikka LINNAKOSKI, Varpu MARJOMÄKI, Petri KILPELÄINEN, Dhanik RESHAMWALA, Henri VANHANEN, Pyry VETELI
  • Vemurafenib and salts thereof for use in the treatment of enteroviral infections
    Publication number: 20210244716
    Abstract: The present invention provides N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide known as vemurafenib, and pharmaceutical salts thereof for use in the treatment of enteroviral diseases.
    Type: Application
    Filed: October 3, 2019
    Publication date: August 12, 2021
    Inventors: Varpu Marjomäki, Mira Laajala, Mari Martikainen
  • Biotin-binding receptor molecules
    Publication number: 20090011984
    Abstract: The subject invention pertains to a transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity, and methods of use. The protein can be expressed in a cell, thereby targeting a biotinylated drug.
    Type: Application
    Filed: April 24, 2007
    Publication date: January 8, 2009
    Inventors: Seppo Yla-Herttuala, Markku Kulomaa, Pauliina Lehtolainen, Varpu Marjomaki, Kari Airenne
  • Nucleic acids encoding biotin-binding receptors
    Patent number: 7208291
    Abstract: The present invention pertains to a novel transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: April 24, 2007
    Assignee: Ark Therapeutics Limited
    Inventors: Seppo Yla-Herttuala, Markku Kulomaa, Pauliina Lehtolainen, Varpu Marjomaki, Kari Airenne
  • Biotin-binding receptor molecules
    Publication number: 20040185059
    Abstract: The present invention pertains to a novel transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity.
    Type: Application
    Filed: July 11, 2003
    Publication date: September 23, 2004
    Inventors: Seppo Yla-Herttuala, Markku Kulomaa, Pauliina Lehtolainen, Varpu Marjomaki, Kari Airenne